These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 38652356)
1. Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines. Zhu C; Pang S; Liu J; Duan Q Drugs; 2024 Apr; 84(4):403-423. PubMed ID: 38652356 [TBL] [Abstract][Full Text] [Related]
2. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 vaccine candidates in rapid development. Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319 [TBL] [Abstract][Full Text] [Related]
6. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
7. Advances in virus-like particle-based SARS-CoV-2 vaccines. Hao X; Yuan F; Yao X Front Cell Infect Microbiol; 2024; 14():1406091. PubMed ID: 38988812 [TBL] [Abstract][Full Text] [Related]
8. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z; Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794 [TBL] [Abstract][Full Text] [Related]
9. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Gong W; Parkkila S; Wu X; Aspatwar A Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216 [TBL] [Abstract][Full Text] [Related]
11. The 2020 race towards SARS-CoV-2 specific vaccines. Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775 [TBL] [Abstract][Full Text] [Related]
12. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
13. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
14. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 Vaccines: Where Did We Stand at the End of 2023? Lundstrom K Viruses; 2024 Jan; 16(2):. PubMed ID: 38399979 [TBL] [Abstract][Full Text] [Related]
17. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
18. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Bian L; Gao F; Zhang J; He Q; Mao Q; Xu M; Liang Z Expert Rev Vaccines; 2021 Apr; 20(4):365-373. PubMed ID: 33851875 [TBL] [Abstract][Full Text] [Related]
19. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732 [TBL] [Abstract][Full Text] [Related]
20. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Sharma O; Sultan AA; Ding H; Triggle CR Front Immunol; 2020; 11():585354. PubMed ID: 33163000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]